887585-71-9

Basic information

• Product Name: (5-bromo-2,3-difluorophenyl)methanol
• Synonyms: (5-bromo-2,3-difluorophenyl)methanol
• CAS NO: 887585-71-9
• Molecular Formula: C₇H₅BrF₂O
• Molecular Weight: 223.0148064
• Mol File: 887585-71-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (5-bromo-2,3-difluorophenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (5-bromo-2,3-difluorophenyl)methanol(887585-71-9)
• EPA Substance Registry System: (5-bromo-2,3-difluorophenyl)methanol(887585-71-9)

Safety Data

• Hazardous Substances Data: 887585-71-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5-bromo-2,3-difluorophenyl)methanol is used as a reagent for the synthesis of various pharmaceutical products. Its unique structure and reactivity make it a key component in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, (5-bromo-2,3-difluorophenyl)methanol is employed as a reagent for the preparation of different agrochemical products. Its contribution to the synthesis of these products aids in enhancing agricultural productivity and crop protection.
Used in Material Science:
(5-bromo-2,3-difluorophenyl)methanol is used as a building block in material science for the synthesis of diverse organic compounds. Its versatile reactivity allows for the creation of novel materials with specific properties, such as improved strength, durability, or chemical resistance.
Used in Medicinal Chemistry:
Within the field of medicinal chemistry, (5-bromo-2,3-difluorophenyl)methanol is utilized as a building block for the synthesis of complex organic molecules with potential therapeutic applications. Its unique structure and reactivity contribute to the development of new drugs and pharmaceutical agents.

Upstream product

• 633327-22-7 5-bromo-2,3-difluorobenzaldehyde 
• 2646-91-5 2,3-difluorobenzaldehyde 

Downstream Products

• 1143502-73-1 5-Bromo-2,3-difluoro-1-(iodomethyl)benzene 
• 1445796-40-6 C₉H₇BrF₂O₂ 
• 1445796-42-8 C₁₂H₁₅F₂NO₃ 
• 1445796-43-9 C₁₂H₁₄F₃NO₂ 
• 1445796-44-0 C₇H₆F₃N 

Relevant articles and documents

POTENT HUMAN NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amytrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.

Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold

Effective delivery of therapeutic drugs into the human brain is one of the most challenging tasks in central nervous system drug development because of the blood-brain barrier (BBB). To overcome the BBB, both passive permeability and efflux transporter liability of a compound must be addressed. Herein, we report our optimization related to BBB penetration of neuronal nitric oxide synthase (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases. Various approaches, including enhancing lipophilicity and rigidity of new inhibitors and modulating the pKa of amino groups, have been employed. In addition to determining inhibitor potency and selectivity, crystal structures of most newly designed compounds complexed to various nitric oxide synthase isoforms have been determined. We have discovered a new analogue (21), which exhibits not only excellent potency (Ki 30 nM) in nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein substrate liability as indicated by an efflux ratio of 0.8 in the Caco-2 bidirectional assay.

HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS

The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Nonpolar nucleoside mimics as active substrates for human thymidine kinases

We describe the use of nonpolar nucleoside analogues of systematically varied size and shape to probe the mechanisms by which the two human thymidine kinases (TK1 and TK2) recognize and phosphorylate their substrate,thymidine. Comparison of polar thymidine with a nonpolar isostere, 2,4- difluorotoluene deoxyriboside, as substrates for the two enzymes establishes that TK1 requires electrostatic complementarity to recognize the thymine base with high efficiency. Conversely, TK2 does not and phosphorylates the hydrophobic shape mimic with efficiency nearly the same as the natural substrate. To test the response to nucleobase size, thymidine-like analogues were systematically varied by replacing the 2,4 substituents on toluene with hydrogen and the halogen series (H, F, Cl, Br, I). Both enzymes showed a distinct preference for substrates having the naturalsize. To examine the shape preference, we prepared four mono- and diflu orotoluene deoxyribosides with varying positions of substitutions. WhileTK1 did not accept these nonpolar analogues as substrates, TK2 did show varying levels of phosphorylation of the shape-varied set. This latter enzyme preferred toluene nucleoside analogues having steric projections at the 2 and 4 positions, as is found in thymine, and strongly disfavore d substitution at the 3-position. Steady-state kinetics measurements showed that the 4-fluoro compound (7) had an apparent Vmax/Kmax value within 14-fold of the natural substrate, and the 2,4-difluoro compound (1), which is the closest isostere of thymidine, had a value within 2.5-fold. The results establish that nucleoside recognition mechanisms for the two classes of enzymes are very different. On the basis of these data, nonpolar nucleosides are likely to be active in the nucleotide salvage pathway in human cells, suggesting new designs for future bioactive molecules.